eXCELL Biotherapeutics Inc.
Selected as a startup company by FINDIT Matchmaking in the past two years
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
eXCELL is an immunotherapy company that uses the body built-in immune rejection responses to non-self cells to combat the difficult-to-treat cancers by utilizing xenogeneic cells that could promote cancer immunity cycle due to the similarities between xen
The content above was translated by Ai
Founded Year
2019
Unified Business No.
82820364
Status
Active
Number of Employees
6
Total Paid-in
Capital
47,533,330 (NT$)
Location of Company
Taiwan
, Taichung City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
To discover, develop, and diver transformative xenogeneic cellular medicines to cancer patients and improve their outcomes. eXCELL is a company dedicated to developing revolutionary therapies to meliorate people’s lives.
The content above was translated by Ai
